What Incyte's 8-K filings say: 7 filings, latest Aug 31, 2026
Incyte filed its latest 8-K with the SEC on Aug 31, 2026. It discusses material contract and pricing pressure.
Public (INCY)Pharmaceutical Manufacturing5,001 to 10,000 employeesincyte.comLinkedIn
- Filed
- Aug 31, 2026
- Filings
- 7
- Signals
- 18
8-K · latest 10
What Incyte's 8-K filings say
- SEC EDGAR
8-K
Filed · 2 signals
Incyte enters new pricing agreement with CMS for key drugs Jakafi and Jakafi XR.
The agreement requires aligning Medicaid pricing with international benchmarks, indicating a proactive strategy to manage government pricing pressure.
- SEC EDGAR
8-K
Filed · 3 signals
Incyte completes acquisition of Vega Therapeutics, a subsidiary of Star Therapeutics.
Star Therapeutics LLC
The acquisition of Vega Therapeutics represents a significant capital deployment and triggers a complex post-merger integration.
Incyte completes acquisition of Vega Therapeutics, triggering post-merger integration activities.
The acquisition of Vega Therapeutics necessitates the integration of two separate organizations, including their operations, technology stacks, and personnel.
- SEC EDGAR
8-K
Filed · 2 signals
Incyte to record $246M benefit after settling CMS litigation over Opzelura drug pricing
The company resolved a lawsuit with the Centers for Medicare & Medicaid Services, resulting in a one-time, non-cash benefit of $246M.
$246M
one-time, non-cash benefit from reversal of previously established accrual balances
Incyte secures $246M benefit and improved margins in CMS settlement for Opzelura
The company resolved litigation with CMS, resulting in a one-time $246M non-cash benefit and improved ongoing gross-to-net margins for its Opzelura product.
$246M
One-time, non-cash benefit from reversal of accrual balances related to a litigation settlement.
- SEC EDGAR
8-K
Filed · 1 signal
Significant shareholder opposition to Director Julian C.
19%
Approximate percentage of shareholder votes cast against Director Julian C. Baker.
Ernst & Young LLP
- SEC EDGAR
8-K
Filed · 3 signals
Incyte announces definitive agreement to acquire Vega Therapeutics on June 8, 2026
Incyte to acquire Vega Therapeutics, triggering post-merger integration initiatives.
The acquisition of Vega Therapeutics will require Incyte to integrate new operations, systems, and personnel.
Star Therapeutics, LLC
- SEC EDGAR
8-K
Filed · 2 signals
Earlier 8-K filings
- 8-KFiled · 5 signalsSEC EDGAR
Showing 10 of 18 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Incyte with the Signal API
One POST /v1/companies/enrich call with incyte.com returns Incyte 8-K signals (sec-8k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"incyte.com","signal_types":["sec-8k"],"limit":20}'Same industry
8-K at related companies
Questions about Incyte 8-K
When did Incyte file its latest 8-K?
What did Incyte disclose in its latest 8-K?
Where can I read Incyte's 8-K filing?
Source. Current reports (Form 8-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .